Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses

Vaccine

Volumn 28, Issue 41, 2010, Pages 6730-6739

  Brandler, Samantha ^a   Ruffie, Claude ^a   Najburg, Valérie ^a   Frenkiel, Marie Pascale ^b   Bedouelle, Hughes ^b   Desprès, Philippe ^b   Tangy, Frédéric ^a  

^a CNRS   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

Dengue; Measles; Vaccine

Indexed keywords

MEASLES VACCINE; MEASLES VACCINE TETRAA; MEASLES VACCINE TETRAB; MEASLES VACCINE TETRAC; MEMBRANE PROTEIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; SEROTYPE; VIRUS ENVELOPE; VIRUS REPLICATION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CERCOPITHECUS AETHIOPS; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DROSOPHILA; ESCHERICHIA COLI; GENETIC VECTORS; IMMUNITY, HUMORAL; IMMUNOLOGIC MEMORY; MALE; MEASLES VACCINE; MICE; MICE, TRANSGENIC; NEUTRALIZATION TESTS; PLASMIDS; RECOMBINANT PROTEINS; VERO CELLS; VIRAL ENVELOPE PROTEINS;

EID: 77956480263     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.073     Document Type: Article

References (87)

1. Halstead S.B. Dengue. Lancet 2007, 370(November (9599)):1644-1652.
2. Lindenbach B.R. Flaviviridae: the viruses and their replication. Fields virology 2001, 991-1041. Lippincott-Williams & Wilkins, Philadelphia, PA. D.H. Knipe (Ed.).
3. Halstead S.B., Nimmannitya S., Cohen S.N. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 1970, 42(April (5)):311-328.
4. Halstead S.B., O'Rourke E.J. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 1977, 265(February (5596)):739-741.
5. Durbin A.P., Whitehead S.S. Dengue vaccine candidates in development. Curr Top Microbiol Immunol 2010, 338:129-143.
6. Edelman R. Dengue vaccines approach the finish line. Clin Infect Dis 2007, 45(July (Suppl. 1)):S56-S60.
7. Lang J. Recent progress on sanofi pasteur's dengue vaccine candidate. J Clin Virol 2009, 46(October (Suppl. 2)):S20-S24.
8. Webster D.P., Farrar J., Rowland-Jones S. Progress towards a dengue vaccine. Lancet Infect Dis 2009, 9(November (11)):678-687.
9. Guirakhoo F., Kitchener S., Morrison D., Forrat R., McCarthy K., Nichols R., et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006, 2(March-April (2)):60-67.
10. Guy B. Immunogenicity of sanofi pasteur tetravalent dengue vaccine. J Clin Virol 2009, 46(October (Suppl. 2)):S16-S19.
11. Guy B., Guirakhoo F., Barban V., Higgs S., Monath T.P., Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue. West Nile and Japanese encephalitis viruses. Vaccine 2010, 28(January (3)):632-649.
12. Simasathien S., Thomas S.J., Watanaveeradej V., Nisalak A., Barberousse C., Innis B.L., et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg 2008, 78(March (3)):426-433.
13. Sun W., Cunningham D., Wasserman S.S., Perry J., Putnak J.R., Eckels K.H., et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum Vaccin 2009, 5(January-February (1)):33-40.
14. Saluzzo J.F. Empirically derived live-attenuated vaccines against dengue and Japanese encephalitis. Adv Virus Res 2003, 61:419-443.
15. Sun W., Edelman R., Kanesa-Thasan N., Eckels K.H., Putnak J.R., King A.D., et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003, 69(December (6 Suppl.)):24-31.
16. Kitchener S., Nissen M., Nasveld P., Forrat R., Yoksan S., Lang J., et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 2006, 24(February (9)):1238-1241.
17. Guy B., Barban V., Mantel N., Aguirre M., Gulia S., Pontvianne J., et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 2009, 80(February (2)):302-311.
18. Rey F.A., Heinz F.X., Mandl C., Kunz C., Harrison S.C. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 1995, 375(May (6529)):291-298.
19. Nayak V., Dessau M., Kucera K., Anthony K., Ledizet M., Modis Y. Crystal structure of dengue virus type 1 envelope protein in the postfusion conformation and its implications for membrane fusion. J Virol 2009, 83(May (9)):4338-4344.
20. Modis Y., Ogata S., Clements D., Harrison S.C. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA 2003, 100(June (12)):6986-6991.
21. Modis Y., Ogata S., Clements D., Harrison S.C. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 2005, 79(January (2)):1223-1231.
22. Nybakken G.E., Nelson C.A., Chen B.R., Diamond M.S., Fremont D.H. Crystal structure of the West Nile virus envelope glycoprotein. J Virol 2006, 80(December (23)):11467-11474.
23. Kanai R., Kar K., Anthony K., Gould L.H., Ledizet M., Fikrig E., et al. Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes. J Virol 2006, 80(November (22)):11000-11008.
24. Stiasny K., Kiermayr S., Holzmann H., Heinz F.X. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol 2006, 80(October (19)):9557-9568.
25. Oliphant T., Nybakken G.E., Austin S.K., Xu Q., Bramson J., Loeb M., et al. The induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol 2007, 81(November (21)):11828-11839.
26. Sanchez M.D., Pierson T.C., Degrace M.M., Mattei L.M., Hanna S.L., Del Piero F., et al. The neutralizing antibody response against West Nile virus in naturally infected horses. Virology 2007, 359(March (2)):336-348.
27. Sukupolvi-Petty S., Austin S.K., Purtha W.E., Oliphant T., Nybakken G.E., Schlesinger J.J., et al. Type- and subcomplex-specific neutralizing antibodies against domain iii of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 2007, 81(December (23)):12816-12826.
28. Rajamanonmani R., Nkenfou C., Clancy P., Yau Y.H., Shochat S.G., Sukupolvi-Petty S., et al. On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. J Gen Virol 2009, 90(April (Pt 4)):799-809.
29. Oliphant T., Engle M., Nybakken G.E., Doane C., Johnson S., Huang L., et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 2005, 11(May (5)):522-530.
30. Nybakken G.E., Oliphant T., Johnson S., Burke S., Diamond M.S., Fremont D.H. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 2005, 437(September (7059)):764-769.
31. Crill W.D., Roehrig J.T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 2001, 75(August (16)):7769-7773.
32. Cecilia D., Gould E.A. Nucleotide changes responsible for loss of neuroinvasiveness in Japanese encephalitis virus neutralization-resistant mutants. Virology 1991, 181(March (1)):70-77.
33. Beasley D.W., Barrett A.D. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J Virol 2002, 76(December (24)):13097-13100.
34. Simmons M., Nelson W.M., Wu S.J., Hayes C.G. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am J Trop Med Hyg 1998, 58(May (5)):655-662.
35. Khanam S., Etemad B., Khanna N., Swaminathan S. Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes. Am J Trop Med Hyg 2006, 74(February (2)):266-277.
36. Hermida L., Rodriguez R., Lazo L., Silva R., Zulueta A., Chinea G., et al. A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J Virol Methods 2004, 115(January (1)):41-49.
37. Hermida L., Rodriguez R., Lazo L., Bernardo L., Silva R., Zulueta A., et al. A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice. Biotechnol Appl Biochem 2004, 39(February (Pt 1)):107-114.
38. Hermida L., Bernardo L., Martin J., Alvarez M., Prado I., Lopez C., et al. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 2006, 24(April (16)):3165-3171.
39. Khanam S., Pilankatta R., Khanna N., Swaminathan S. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine 2009, 27(October (43)):6011-6021.
40. Combredet C., Labrousse-Najburg V., Mollet L., Lorin C., Delebecque F., Hurtrel B., et al. A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol 2003, 77(21):11546-11554.
41. Griffin D. Measles virus. Field's virology 2001, 1401-1441. Lippincott-Raven Publishers, Philadelphia. 4th ed. D. Knipe, P. Howley (Eds.).
42. Naniche D., Garenne M., Rae C., Manchester M., Buchta R., Brodine S.K., et al. Decrease in measles virus-specific CD4 T cell memory in vaccinated subjects. J Infect Dis 2004, 190(October (8)):1387-1395.
43. Ovsyannikova I., Dhiman N., Jacobson R., Vierkant R., Poland G. Frequency of measles virus-specific CD4+ and CD8+ T cells in subjects seronegative or highly seropositive for measles vaccine. Clin Diagn Lab Immunol 2003, 10(3):411-416.
44. Desprès P., Combredet C., Frenkiel M., Lorin C., Brahic M., Tangy F. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis 2005, 191(2):207-214.
45. Guerbois M., Moris A., Combredet C., Najburg V., Ruffie C., Fevrier M., et al. Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic. Virology 2009, 388(May (1)):191-203.
46. Lorin C., Saidi H., Belaid A., Zairi A., Baleux F., Hocini H., et al. The antimicrobial peptide dermaseptin S4 inhibits HIV-1 infectivity in vitro. Virology 2005, 334(April (2)):264-275.
47. Lorin C., Mollet L., Delebecque F., Combredet C., Charneau P., Hurtrel B., et al. A single injection of recombinant measles vaccines expressing HIV-1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J Virol 2004, 78(1):146-157.
48. Brandler S., Tangy F. Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines. Comp Immunol Microbiol Infect Dis 2008, 31(March (2/3)):271-291.
49. Brandler S., Lucas-Hourani M., Moris A., Frenkiel M.P., Combredet C., Fevrier M., et al. Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Negl Trop Dis 2007, 1(3):e96.
50. Bressanelli S., Stiasny K., Allison S.L., Stura E.A., Duquerroy S., Lescar J., et al. Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J 2004, 23(February (4)):728-738.
51. Henchal E.A., Gentry M.K., McCown J.M., Brandt W.E. Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am J Trop Med Hyg 1982, 31(July (4)):830-836.
52. Wahala W.M., Donaldson E.F., de Alwis R., Accavitti-Loper M.A., Baric R.S., de Silva A.M. Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog 2010, 6(3):e1000821.
53. Morens D.M., Halstead S.B. Measurement of antibody-dependent infection enhancement of four dengue virus serotypes by monoclonal and polyclonal antibodies. J Gen Virol 1990, 71(December (Pt 12)):2909-2914.
54. Cathomen T., Mrkic B., Spehner D., Drillien R., Naef R., Pavlovic J., et al. A matrix-less measles virus is infectious and elicits extensive cell fusion: consequences for propagation in the brain. EMBO J 1998, 17(July (14)):3899-3908.
55. Singh M., Cattaneo R., Billeter M.A. A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J Virol 1999, 73(6):4823-4828.
56. Wu S.J., Hayes C.G., Dubois D.R., Windheuser M.G., Kang Y.H., Watts D.M., et al. Evaluation of the severe combined immunodeficient (SCID) mouse as an animal model for dengue viral infection. Am J Trop Med Hyg 1995, 52(May (5)):468-476.
57. Williams K.L., Zompi S., Beatty P.R., Harris E. A mouse model for studying dengue virus pathogenesis and immune response. Ann N Y Acad Sci 2009, 1171(September (Suppl. 1)):E12-E23.
58. Wu-Hsieh B.A., Yen Y.T., Chen H.C. Dengue hemorrhage in a mouse model. Ann N Y Acad Sci 2009, 1171(September (Suppl. 1)):E42-E47.
59. Yauch L.E., Shresta S. Mouse models of dengue virus infection and disease. Antiviral Res 2008, 80(November (2)):87-93.
60. Lin Y.L., Liao C.L., Chen L.K., Yeh C.T., Liu C.I., Ma S.H., et al. Study of Dengue virus infection in SCID mice engrafted with human K562 cells. J Virol 1998, 72(December (12)):9729-9737.
61. Kuruvilla J.G., Troyer R.M., Devi S., Akkina R. Dengue virus infection and immune response in humanized RAG2(-/-)gamma(c)(-/-) (RAG-hu) mice. Virology 2007, 369(December (1)):143-152.
62. Mota J., Rico-Hesse R. Humanized mice show clinical signs of dengue fever according to infecting virus genotype. J Virol 2009, 83(September (17)):8638-8645.
63. Jaiswal S., Pearson T., Friberg H., Shultz L.D., Greiner D.L., Rothman A.L., et al. Dengue virus infection and virus-specific HLA-A2 restricted immune responses in humanized NOD-scid IL2rgammanull mice. PLoS One 2009, 4(10):e7251.
64. Halstead S.B., Deen J. The future of dengue vaccines. Lancet 2002, 360(October (9341)):1243-1245.
65. Hombach J., Barrett A.D., Cardosa M.J., Deubel V., Guzman M., Kurane I., et al. Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand. Vaccine 2005, 23(April (21)):2689-2695.
66. Catteau A., Roue G., Yuste V.J., Susin S.A., Despres P. Expression of dengue ApoptoM sequence results in disruption of mitochondrial potential and caspase activation. Biochimie 2003, 85(August (8)):789-793.
67. Tangy F., Naim H. Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector. Viral Immunol 2005, 18:317-326.
68. Thullier P., Demangel C., Bedouelle H., Megret F., Jouan A., Deubel V., et al. Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J Gen Virol 2001, 82(August (Pt 8)):1885-1892.
69. Bedouelle H., Belkadi L., England P., Guijarro J.I., Lisova O., Urvoas A., et al. Diversity and junction residues as hotspots of binding energy in an antibody neutralizing the dengue virus. FEBS J 2006, 273(January (1)):34-46.
70. Lisova O., Hardy F., Petit V., Bedouelle H. Mapping to completeness and transplantation of a group-specific, discontinuous, neutralizing epitope in the envelope protein of dengue virus. J Gen Virol 2007, 88(September (Pt 9)):2387-2397.
71. Lazo L., Zulueta A., Hermida L., Blanco A., Sanchez J., Valdes I., et al. Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice. Biotechnol Appl Biochem 2009, 52(April (Pt 4)):265-271.
72. Edelman R., Wasserman S.S., Bodison S.A., Putnak R.J., Eckels K.H., Tang D., et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 2003, 69(December (6 Suppl.)):48-60.
73. Etemad B., Batra G., Raut R., Dahiya S., Khanam S., Swaminathan S., et al. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. Am J Trop Med Hyg 2008, 79(September (3)):353-363.
74. Volk D.E., Lee Y.C., Li X., Thiviyanathan V., Gromowski G.D., Li L., et al. Solution structure of the envelope protein domain III of dengue-4 virus. Virology 2007, 364(July (1)):147-154.
75. Guirakhoo F., Pugachev K., Zhang Z., Myers G., Levenbook I., Draper K., et al. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 2004, 78(May (9)):4761-4775.
76. Zulueta A., Martin J., Hermida L., Alvarez M., Valdes I., Prado I., et al. Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res 2006, 121(October (1)):65-73.
77. Kalayanarooj S., Nimmannitya S. Clinical presentations of dengue hemorrhagic fever in infants compared to children. J Med Assoc Thai 2003, 86(August (Suppl. 3)):S673-S680.
78. Halstead S.B., Lan N.T., Myint T.T., Shwe T.N., Nisalak A., Kalyanarooj S., et al. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg Infect Dis 2002, 8(December (12)):1474-1479.
79. Pengsaa K., Luxemburger C., Sabchareon A., Limkittikul K., Yoksan S., Chambonneau L., et al. Dengue virus infections in the first 2 years of life and the kinetics of transplacentally transferred dengue neutralizing antibodies in thai children. J Infect Dis 2006, 194(December (11)):1570-1576.
80. Despres P., Frenkiel M.P., Ceccaldi P.E. Duarte Dos Santos C, Deubel V. Apoptosis in the mouse central nervous system in response to infection with mouse-neurovirulent dengue viruses. J Virol 1998, 72(January (1)):823-829.
81. Deubel V., Kinney R.M., Trent D.W. Nucleotide sequence and deduced amino acid sequence of the nonstructural proteins of dengue type 2 virus, Jamaica genotype: comparative analysis of the full-length genome. Virology 1988, 165(July (1)):234-244.
82. Radecke F., Spielhofer P., Schneider H., Kaelin K., Huber M., Dotsch C., et al. Rescue of measles viruses from cloned DNA. EMBO J 1995, 14(23):5773-5784.
83. Parks C.L., Lerch R.A., Walpita P., Sidhu M.S., Udem S.A. Enhanced measles virus cDNA rescue and gene expression after heat shock. J Virol 1999, 73(5):3560-3566.
84. Duarte dos Santos C.N., Frenkiel M.P., Courageot M.P., Rocha C.F., Vazeille-Falcoz M.C., Wien M.W., et al. Determinants in the envelope E protein and viral RNA helicase NS3 that influence the induction of apoptosis in response to infection with dengue type 1 virus. Virology 2000, 274(September (2)):292-308.
85. Sambrook J., Russel D.W. Molecular cloning: a laboratory manual 2001.
86. Lucas M., Mashimo T., Frenkiel M.-P., Simon-Chazottes D., Montagutelli X., Ceccaldi P.-E., et al. Infection of mouse neurons by West Nile virus is modulated by the interferon-inducible 2'-5'oligoadenylate synthetase 1b protein. Immun Cell Biol 2003, 81:230-236.
87. Navarro-Sanchez E., Altmeyer R., Amara A., Schwartz O., Fieschi F., Virelizier J.L., et al. Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep 2003, 4(July (7)):723-728.